To get the cosmetics or items you want, it's better to first understand how the Ode system works. Each type of Ode has its own structure and drop rates, so learning the basics lets you plan your pulls ...

Nahda Nabiilah is a writer and editor from Indonesia. She has always loved writing and playing games, so one day she decided to combine the two. Most of the time, writing gaming guides is a blast for ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

Helm of the Dominator catapulted as the star item in Dota 2 The International 2025, a.k.a TI14. The item's sudden rise in the meta can be attributed to several factors, most notably its regeneration ...

Donavan Brazier won the men's 800 at 2025 USATF Championships, but high schooler Cooper Lutkenhaus stole the spotlight. Here are the results. Donavan Brazier may have won the men's 800-meter race at ...

Peter earned a Bachelor of Archeology and Creative Writing from the University of Alabama and has since joined his love of driving and riding with storytelling. His voice is full of southern ...

President Trump is ending an exemption that allowed certain low-value commercial shipments into the United States without facing tariffs. Trump signed an executive order that will end the so-called de ...

Running shorts were not made for carrying stuff. The best running belts, however, actually allow you to tote all your gear on your runs without sacrificing mile time or comfort. A ton of shorts are ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...